Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laetitia A Mauti

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Translational Cancer Research|July 21, 2025
<i>ROS1</i> fusion-positive non-small cell lung cancer-repotrectinib as a new treatment optionSacha I Rothschild, Laetitia A Mauti
The Journal of Clinical Investigation|June 8, 2011
Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestationLaetitia A Mauti, Marie-Aude Le Bitoux, Karine Baumer, et al.
Journal of Clinical Medicine|March 29, 2023
Only EBUS-Guided Mediastinal Lymph Node Cryobiopsy Enabled Immunotherapy in a Patient with Non-Small Cell Lung CancerJürgen Hetzel, Laetitia A Mauti, Jonas Winkler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 7, 2024
Lung Cancer in SwitzerlandRaphael Sven Werner, Alessandra Curioni-Fontecedro, Laetitia A Mauti, et al.
Cancer Immunology, Immunotherapy : CII|April 21, 2020
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohortSabine Schmid, Laetitia A Mauti, Alex Friedlaender, et al.
Lung Cancer (Amsterdam, Netherlands)|November 11, 2025
First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastasesLorenz Frehner, Sämi Schär, Stefanie Hayoz, et al.
JTO Clinical and Research Reports|December 3, 2024
Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line TreatmentSabine Schmid, Lisa Holer, Katrin Gysel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 25, 2018
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural MesotheliomaYannis Metaxas, Gareth Rivalland, Laetitia A Mauti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2021
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II TrialSacha I Rothschild, Alfred Zippelius, Eric I Eboulet, et al.
Nature Communications|September 30, 2025
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapyDominic Schmid, Bettina Sobottka, Massimiliano Manzo, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Translational Cancer Research|July 21, 2025
<i>ROS1</i> fusion-positive non-small cell lung cancer-repotrectinib as a new treatment optionSacha I Rothschild, Laetitia A Mauti
The Journal of Clinical Investigation|June 8, 2011
Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestationLaetitia A Mauti, Marie-Aude Le Bitoux, Karine Baumer, et al.
Journal of Clinical Medicine|March 29, 2023
Only EBUS-Guided Mediastinal Lymph Node Cryobiopsy Enabled Immunotherapy in a Patient with Non-Small Cell Lung CancerJürgen Hetzel, Laetitia A Mauti, Jonas Winkler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 7, 2024
Lung Cancer in SwitzerlandRaphael Sven Werner, Alessandra Curioni-Fontecedro, Laetitia A Mauti, et al.
Cancer Immunology, Immunotherapy : CII|April 21, 2020
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohortSabine Schmid, Laetitia A Mauti, Alex Friedlaender, et al.
Lung Cancer (Amsterdam, Netherlands)|November 11, 2025
First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastasesLorenz Frehner, Sämi Schär, Stefanie Hayoz, et al.
JTO Clinical and Research Reports|December 3, 2024
Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line TreatmentSabine Schmid, Lisa Holer, Katrin Gysel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 25, 2018
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural MesotheliomaYannis Metaxas, Gareth Rivalland, Laetitia A Mauti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2021
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II TrialSacha I Rothschild, Alfred Zippelius, Eric I Eboulet, et al.
Nature Communications|September 30, 2025
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapyDominic Schmid, Bettina Sobottka, Massimiliano Manzo, et al.
Pageof 2